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Background andRationale: ICU clinicians regularly care for patients
who lack capacity, an applicable advance directive, and an available
surrogate decision-maker. Although there is no consensus on
terminology, we refer to these patients as “unrepresented.” There is
considerable controversy abouthowtomake treatmentdecisions for these
patients, and there is significantvariability inboth lawandclinicalpractice.
Purpose and Objectives: This multisociety statement provides
clinicians and hospital administrators with recommendations for
decision-making on behalf of unrepresented patients in the critical
care setting.
Methods: An interprofessional, multidisciplinary expert committee
developed this policy statement by using an iterative consensus
process with a diverse working group representing critical care
medicine, palliative care, pediatric medicine, nursing, social work,
gerontology, geriatrics, patient advocacy, bioethics, philosophy, elder
law, and health law.
MainResults: The committee designed its policy recommendations
to promote five ethical goals: 1) to protect highly vulnerable patients,
2) to demonstrate respect for persons, 3) to provide appropriate
medical care, 4) to safeguard against unacceptable discrimination,
and 5) to avoid undue influence of competing obligations and
conflicting interests. These recommendations also are intended to
strike an appropriate balance between excessive and insufficient
procedural safeguards. The committee makes the following
recommendations: 1) institutions should offer advance care planning
to prevent patients at high risk for becoming unrepresented from
meeting this definition; 2) institutions should implement strategies to
determine whether seemingly unrepresented patients are actually
unrepresented, including careful capacity assessments and diligent
searches for potential surrogates; 3) institutions should manage
decision-making for unrepresented patients using input from
a diverse interprofessional, multidisciplinary committee rather than
ad hoc by treating clinicians; 4) institutions should use all available
information on the patient’s preferences and values to guide
treatment decisions; 5) institutions should manage decision-making
for unrepresented patients using a fair process that comports with
procedural due process; 6) institutions should employ this fair
process even when state law authorizes procedures with less
oversight.
Conclusions: This multisociety statement provides guidance for
clinicians and hospital administrators on medical decision-making
for unrepresented patients in the critical care setting.
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Overview
ICU clinicians regularly face situations in
which an adult patient lacks decision-
making capacity, an applicable advance
directive, and any available surrogate
decision-maker (1–6). For these patients,
there is no one with whom the clinician can
engage in shared decision-making, which is
recommended for important, value-laden
decisions in ICUs (7). Available evidence
shows that the absence of a decision-maker
causes patients to face significant risks
of being overtreated, undertreated, or
otherwise treated inconsistently with their
preferences and values (8–10).
This policy statement refers to these
patients as “unrepresented patients.” Yet,
there is no consensus on which term to
use, and others use “unbefriended” or
“incapacitated patient without advocate”
(11). In addition to terminology, there is
considerable controversy over how to make
medical treatment decisions for these
patients (12). Moreover, in the ICU setting,
there is significant variability in how
decisions are made and little guidance
about how to do so (2).
The committee developed this policy
statement to help clinicians and hospital
administrators design fair and feasible
procedures for making treatment decisions
for unrepresented patients in the ICU
setting. This policy statement provides 1) an
ethical analysis of medical decision-making
for unrepresented patients, 2)
recommended decision-making procedures
for unrepresented patients in the critical
care setting, and 3) proposed components
of a model institutional policy on decision-
making for unrepresented patients in ICUs.
The six recommendations described
below have two primary justifications. First,
they promote the following five ethical goals:
1) to protect highly vulnerable patients, 2)
to demonstrate respect for persons, 3) to
provide appropriate medical care, 4) to
safeguard against unacceptable
discrimination, and 5) to avoid the undue
influence of competing obligations and
conflicting interests. Second, the six
recommendations help strike an
appropriate balance between excessive and
insufficient procedural safeguards.
Excessive safeguards may delay providing
patients with appropriate medical care and
may be too cumbersome for clinicians and
institutions. Insufficient safeguards may fail
to adequately promote the five ethical goals.
Recommendation 1
Institutions should promote advance care
planning to prevent patients at high risk
from becoming unrepresented in the first
place, both 1) by helping adult patients with
decision-making capacity to identify
a preferred surrogate decision-maker and to
record their preferences and values in an
advance directive and 2) by ensuring that
such documents are available to clinicians
at the point of care.
Recommendation 2
Institutions should implement strategies
to determine whether seemingly
unrepresented patients are, in fact,
unrepresented by 1) carefully assessing
medical decision-making capacity, 2)
diligently searching for suitable surrogates
among the patient’s family and friends, and
3) involving any nonhospital individuals
who have shown care and concern for the
patient’s welfare and are familiar with the
patient’s values and preferences.
Recommendation 3
Institutions should manage decision-
making for unrepresented patients using
collaboration between the clinical team and
a diverse interprofessional,
multidisciplinary committee rather than ad
hoc by treating clinicians.
Recommendation 4
Institutions should use all available
information on the patient’s preferences and
values to guide decisions. If such information
is not available, the committee should
collaborate with the treatment team to make
decisions in the patient’s best interest.
Recommendation 5
Institutions should manage decision-
making for unrepresented patients using
a fair process that comports with principles
of procedural due process, such as
transparency, legitimacy, and consistency.
Recommendation 6
Institutions should employ this fair process
even when state law authorizes procedures
with less oversight.
Introduction
ICU clinicians regularly face situations in
which an adult patient lacks both decision-
making capacity and any available surrogate
decision-maker (1–6). For these patients,
there is no one with whom the clinician can
engage in shared decision-making, which is
recommended for important, value-laden
decisions in ICUs (7). Available evidence
shows that the absence of a decision-maker
causes patients to face significant risks of
being overtreated, undertreated, or
otherwise treated inconsistently with their
preferences and values (8–10).
This policy statement refers to these
patients as “unrepresented patients.” Yet,
there is no consensus on which term to use,
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and others use “unbefriended” or
“incapacitated patient without advocate”
(11). There is considerable controversy over
how to make medical treatment decisions
for these patients (11, 12). Moreover, in the
ICU setting, there is significant variability
in how decisions are made and little
guidance about how to do so (2).
Unrepresented patients in the critical
care setting are common (5). In 2006, White
and colleagues found that 16% of patients
admitted to an ICU were unrepresented (1).
In 2007, White and colleagues found that 5%
of patients who died in the ICU were
unrepresented (2). In a more recent survey of
critical care clinicians and hospitalists, nearly
50% of respondents reported seeing at least
one unrepresented patient per month (3).
Other studies measuring the number of
unrepresented patients in other healthcare
settings corroborate these figures (4, 6, 13).
Incapacitated critically ill patients
without an applicable advance directive or
a surrogate decision-maker leave clinicians
in a quandary. Providers in the United States
generally take three different approaches: 1)
providing treatment, 2) withholding or
withdrawing treatment, or 3) delaying
treatment. First, some clinicians might treat
the patient without consent. Erring on the
side of prolonging life, they may administer
improperly prolonged life-sustaining
treatment despite limited prospects of
benefit, despite burdens on the patient, and
even despite evidence of the patient’s
wishes to avoid such treatment (5, 14).
Second, some clinicians might withhold or
withdraw treatment because they
unilaterally deem it to be potentially
inappropriate. Third, other clinicians may
delay treatment until the patient regains
capacity or a court-appointed surrogate
decision-maker is identified.
These inconsistencies are ethically
problematic. Furthermore, this variability in
care exposes unrepresented patients to three
different types of risks: overtreatment,
undertreatment, and delayed treatment. In
addition, because there is no one to authorize
discharge, the unrepresented often have
prolonged hospital stays. ICU stays for
unrepresented patients are often twice the
duration of stays for other patients (9, 10).
Although several professional societies
have published policy statements regarding
decision-making for unrepresented patients
(11, 15, 16), none specifically addresses
decision-making for unrepresented patients
in the critical care setting. Moreover, these
guidelines differ substantially on who may
act as a surrogate and authorize treatment
decisions on behalf of unrepresented
patients (Table 1). State healthcare
surrogate laws vary as well (Table 2) (3,
17–19). These conflicting laws and
conflicting guidelines from professional
societies are problematic. This variability
may exacerbate confusion on this topic
among clinicians, hospital administrators,
and policy makers (15, 20–22).
Both because of these complexities and
because clinicians need clear guidance, the
American Thoracic Society (ATS) convened
a multisociety working group to make
recommendations regarding how to make
treatment decisions for unrepresented
patients in the context of acute critical
illness. This ATS/American Geriatrics
Society (AGS) policy statement provides
clinicians and hospital administrators with
guidelines for medical treatment decision-
making on behalf of unrepresented patients.
The committee developed this policy
statement to help clinicians and hospital
administrators design fair and feasible
procedures for making treatment decisions
for unrepresented patients in the ICU
setting. This policy statement provides 1) an
ethical analysis of medical decision-making
for unrepresented patients, 2)
recommended decision-making procedures
for unrepresented patients in the critical
care setting, and 3) proposed components
of a model institutional policy on decision-
making for unrepresented patients in ICUs.
This policy statement focuses on
decisions regarding life-sustaining
treatment for adult patients. It does
not address 1) decision-making for
unrepresented patients outside the ICU
setting, 2) decision-making for biomedical
research purposes, 3) decision-making in
emergencies, or 4) decisions regarding
organ donation and other postmortem
decisions. This policy statement also
does not address decisions for minor
interventions that are less consequential
and may require less process and oversight
(e.g., administration of most drugs and
vaccines or the performance of minor
procedures, such as routine X-rays) (7, 23).
Methods
An interprofessional, multidisciplinary
expert committee developed this policy
statement using an iterative process. The
ATS Ethics and Conflict of Interest
Committee first convened an ad hoc
working group composed of a subset of
members of the ATS Ethics and Conflict
of Interest Committee. The committee
evaluated the need for additional expertise
and invited 20 national experts to join the
working group. The full working group was
diverse and represented a breadth of
disciplines, including critical care medicine,
palliative care, pediatric medicine, nursing,
social work, gerontology, geriatrics, patient
advocacy, bioethics, philosophy, elder law,
and health law.
The working group first reviewed
known relevant literature, including journals
with a focus in medicine, critical care,
bioethics, and law. The group deemed this
broad approach appropriate because this
document is a policy statement that relies
heavily on theoretical analysis informed by
available research data and is not intended to
be considered a practice guideline. The group
also reviewed existing policies of other
medical organizations. The group then
developed the content of this policy through
a 3-year iterative discussion–based consensus
process consisting of face-to-face meetings,
teleconferences, web conferences, and
electronic correspondence. A writing
committee drafted the policy statement,
which the working group members then
reviewed on multiple occasions and revised.
The policy statement was further modified
and ultimately approved by members of the
ATS and AGS ethics committees. This
statement then underwent a peer review
process and ultimately review by both the
ATS Board of Directors and the AGS Board
of Directors.
Ethical Goals for Decision-
Making for Unrepresented
Patients
A review of the literature on unrepresented
patients reveals five key reasons why
guarded diligence and careful evaluation are
required when making treatment decisions
for unrepresented patients: 1) to protect
highly vulnerable patients, 2) to
demonstrate respect for persons, 3) to
provide appropriate medical care, 4)
to safeguard against unacceptable
discrimination, and 5) to avoid undue
influence of competing obligations and
interests (Table 3).
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Protect Highly Vulnerable Patients
Unrepresented patients in the ICU are
extremely vulnerable in several ethically
relevant ways (24). First, patients in ICUs
cannot advocate for themselves, because
they frequently lack decision-making
capacity owing to the severity of their
illness and/or sedative and pain-relieving
medications (7, 25, 26). Second,
unrepresented patients lack trusted and
reliable friends or family to advocate on
their behalf. Third, when admitted to an
ICU, patients (including unrepresented
patients) usually lack a choice of healthcare
clinician. They are completely dependent
on the institution and its clinicians. For all
these reasons, commentators have
described unrepresented ICU patients as
“unimaginably helpless” (27), as “highly
vulnerable” (11), and as the “most
vulnerable” (11).
Demonstrate Respect for Persons
Although manifesting respect for patient
autonomy is a core principle of medical
ethics, it is generally not applicable in the
context of making decisions regarding life-
sustaining treatment for unrepresented
patients. This is because respecting
a patient’s autonomy requires the patient to
have expressed an autonomous treatment
preference applicable to the clinical
situation at hand. By definition,
unrepresented patients cannot currently
articulate treatment preferences specific to
the clinical decision at hand. Most have not
done so previously, and even if they have,
evidence of those preferences is usually not
available (28).
This committee proposes that the
broader ethical goal of manifesting respect
for persons should be viewed as central to
care processes for unrepresented patients.
Respect in this context involves both the
attitudes one adopts toward the
unrepresented patient and the behaviors one
manifests. Respect for persons requires an
acknowledgment of each person’s worth
and dignity. The display of respect can take
on numerous forms, such as making
extensive efforts to learn about and treat the
patient as a unique individual,
incorporating all that is known about the
patient’s values into treatment decisions,
ensuring serious moral deliberation about
decisions, and encouraging others to adopt
a demeanor of sincere regard and caring for
the person in all interactions.
Learning and incorporating the
patient’s individuality, values, goals, culture,
and previously expressed treatment
preferences manifests respect for persons,
a core ethical obligation of the medical
profession (7, 24). Physical harm is not
the only type of risk posed to the
unrepresented. Whether overtreated or
undertreated, the unrepresented are
susceptible to treatment decisions that do
not conform to their personal values,
morals, or beliefs. This is a serious affront
to respect for persons.
The Institute of Medicine observes that
patients “who have neither decision-
making capacity nor a surrogate decision-
maker are at particular risk of not having
their wishes known or followed” (8). For
instance, several studies report that
clinicians often make decisions based
on their own idiosyncratic personal
preferences. They may not know the
patient, or they may not be willing and/or
able to take the time to learn the patient’s
preferences (29, 30). A treatment decision
that is not based on a patient’s own
preferences and values, when ascertainable,
is particularly offensive in a society that
places a premium on individual self-
determination (7).
Provide Appropriate Medical Care
In addition to the risk of disrespect for
persons, unrepresented patients face three
types of treatment risk: overtreatment,
undertreatment, or delayed treatment. In
overtreated patients, the absence of an
authorized surrogate often results in
“maximum medical intervention, whether
or not a medical ‘full court press’ is
clinically and ethically warranted” (31).
There are several reasons why the
unrepresented receive unnecessary or
unwanted treatment, including 1)
clinicians’ fear of not providing appropriate
treatment, 2) fear of civil liability for failure
to treat, 3) institutional fear of regulatory
sanctions, 4) clinicians’ economic
incentives to treat, and 5) clinicians’ general
interventionist philosophy of medicine.
Most unrepresented patients are
overtreated, but some are undertreated.
With no surrogate to object, some clinicians
may decide that treatment is inappropriate
and unilaterally withhold or withdraw it.
Table 1. Existing Policy Statements Pertaining to Unrepresented Patients
Year Author/Society Decision-Maker
1992 New York State Task Force on Life
and the Law
Interprofessional, multidisciplinary committee
2003 American Bar Association Interprofessional, multidisciplinary committee
2006 Los Angeles County Medical
Association
Interprofessional, multidisciplinary committee
2015 California Hospital Association Interprofessional, multidisciplinary committee
2016 American Medical Association Hospital ethics committee
2016 American Geriatrics Society Institutional committee (e.g., ethics) or
healthcare team according to
a standardized process
2017 Veterans Health Administration Interprofessional, multidisciplinary
committee1 chief of staff1 facility director
2019 American College of Physicians Court-appointed guardian
Table 2. State Healthcare Surrogate Decision Laws Pertaining to Unrepresented
Patients
State Decision-Maker
Connecticut, Nebraska, North Carolina, North
Dakota, Oregon
Attending alone
Arizona, Arkansas, Louisiana, Tennessee, Texas Attending1 second physician
Alabama Attending1 ethics committee
California Interdisciplinary team
Colorado, Montana Medical proxy1 ethics committee
Florida Independent clinical social worker
Texas Member of clergy
New York Court
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents 1185
Other clinicians may refuse to provide any
type of treatment without informed consent.
Consequently, important decisions may be
“postponed dangerously [or] forgone
altogether” (32, 33).
Some clinicians will wait until an
emergency, when consent is implied and
therefore there is no need for a surrogate to
authorize treatment (3). However, waiting
for an emergency may result in longer
periods of suffering and indignity,
increasing the chance of morbidity or even
mortality. The absence of a surrogate can
“stymie decision-making and possibly
leave . . . patients to linger in pain and
discomfort” (34). The Institute of Medicine
found it ethically “troublesome” to wait
“until the patient’s medical condition
worsens into an emergency so consent to
treat is implied.” Such an approach
“compromises patient care and prevents
any thorough and thoughtful consideration
of patient preferences or best interest” (8).
Safeguard against Unacceptable
Discrimination
Clinicians’ treatment decisions may be
influenced by medically irrelevant
characteristics of the patient (e.g., the
patient’s race, gender, religion, social worth,
undocumented immigration status, ethnicity,
or sexual orientation) rather than by the
nature of the medical service (35–40). It is
unacceptable discrimination to treat a class
of persons unequally on the basis of
medically irrelevant characteristics. Such
conduct is unethical and condemned by
most health care professions’ codes of ethics.
Not only intentional but also implicit
biases may go unchecked without
a surrogate to whom clinicians must explain
and justify their recommendations (41, 42).
The risk of unacceptable discrimination is
especially germane, because unrepresented
patients are often members of groups
(e.g., homeless and those with mental illness
and substance use disorders) that have been
subject to discrimination (43). Furthermore,
there is a risk that treatment decisions will be
influenced not only by irrelevant patient
characteristics but also by irrelevant clinician
characteristics, such as their own personal
preferences for life-extending care or their
religious beliefs (44, 45).
Avoid Undue Influence of Competing
Obligations and Conflicting Interests
Competing obligations occur when
clinicians have two or more valid
professional responsibilities that conflict.
Increasingly, clinicians are perceived to
have ethical commitments both to
individual patients and to society at large to
manage resources in a cost-conscious
manner. When clinicians act as decision-
makers for their patients, there may be
greater likelihood that the patient’s
interests are not adequately represented,
considered, and balanced against the
obligation to populations of patients (12,
46).
A related but distinct concern is that
clinicians’ real or perceived conflicts of
interest may compromise their ability
to act as decision-maker for an
unrepresented patient. At least two types
of secondary interests could unduly
influence the clinician’s professional
judgment about the well-being of the
unrepresented patient. First, financial
interests of the clinician and/or institution
could be affected by treatment decisions.
For example, potential conflict could lead
to overtreatment of patients in fee-for-
service reimbursement models and to
undertreatment in capitated models.
Pressure to make scarce ICU beds
available could also lead to
undertreatment.
Second, clinicians face nonfinancial
conflicts of interest. ICU clinicians generally
work as part of an interprofessional,
multidisciplinary team. To some degree,
their professional satisfaction and
advancement depend on good relationships
with colleagues. End-of-life care often
causes disagreement and moral conflict or
distress among staff. Clinicians have an
interest in maintaining cordial peer
relationships and therefore in making
decisions that will keep peace in the ICU.
This will push toward overtreatment in
some institutions and undertreatment in
others.
Recommendations
Institutions should heed six
recommendations outlined below (Table 4).
They are designed to promote the five
ethical goals. They are also intended to
strike an appropriate balance between
excessive and insufficient procedural
safeguards. Excessive safeguards may
unnecessarily delay providing patients
appropriate medical care and may be too
cumbersome for clinicians and institutions.
Insufficient safeguards fail to adequately
promote the five ethical goals.
Recommendation 1
Institutions should promote advance care
planning to prevent patients at high risk
for becoming unrepresented from
meeting this definition, both 1) by
helping adult patients with decision-
making capacity to identify a preferred
surrogate decision-maker and to record
their preferences and values in an advance
directive and 2) by ensuring that such
documents are widely available to
clinicians at the point of care.
Ideally, potentially unrepresented
patients would engage in advance care
planning in the community in places of
worship, homeless shelters, social support
agencies, legal aid offices, and primary care
offices. Unfortunately, limited time and
training constrain these discussions in the
clinical environment. However, advance
care planning can be effectively
implemented in the hospital or ICU. Indeed,
this is specifically mandated by the Patient
Self Determination Act (47). Several studies
found that although most ICU patients lack
capacity, at least one-fourth remain
involved with their treatment (37, 48).
Many patients can name a surrogate after
admission but before losing capacity (49).
Moreover, even if patients’ capacity is
impaired, they might still have capacity to
share what they think about death, life, their
current living situation, and their hopes for
the future. In short, unrepresented patients
should participate in making decisions to the
extent that they can (50). Given that naming
a preferred surrogate may not require as
much decisional capacity as creating a living
will expressing end-of-life treatment
preferences, this “first step” in advance care
planning should be encouraged upon
admission or during periods of lucidity and
documented when possible (23).
Table 3. Five Ethical Goals for
Safeguards in Decision-Making for
Unrepresented Patients
1. Protect highly vulnerable patients
2. Demonstrate respect for persons
3. Provide appropriate medical care
4. Safeguard against unacceptable
discrimination
5. Avoid undue influence of competing
obligations and conflicting interests
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Recommendation 2
Institutions should implement strategies
to determine whether seemingly
unrepresented patients are, in fact,
unrepresented, including 1) carefully
assessing capacity, 2) diligently searching
for potential surrogates among the
patient’s family and friends, and 3)
involving any nonhospital individuals
who have shown care and concern for the
patient’s welfare and are familiar with the
patient’s values and preferences.
Assess capacity carefully. The best
person to make healthcare decisions for the
patient is the patient herself. With support,
time, and good communication, some
individuals who initially appear to lack
capacity in fact may be able to make their
own decisions (51). For example, language
barriers, sensory deficits, and limited
health literacy are sometimes confused
with a lack of capacity. Too often,
clinicians erroneously assess patients as
lacking capacity to make their own
treatment decisions.
Second, capacity is not all or nothing; it
is decision specific. Several studies found
that although most ICU patients lack
capacity to make decisions about life-
sustaining treatment, approximately one-
fourth to one-third still have at least partial
capacity (37, 48). For example, although
patients may lack the capacity to make
complex treatment decisions, they may
have sufficient capacity to appoint
a surrogate. Moreover, the ability of
critically ill patients to participate in
decision-making often fluctuates over the
course of their illness trajectory (7).
Third, loss of decisional capacity may
be transient. Delirium caused by infection,
poorly controlled pain, sedating medications,
or other substances may temporarily cloud the
patient’s decisional capacity. These conditions
may be superimposed on psychological
conditions such as grief, anxiety, or depression
or sensory deficits such as hearing or vision
loss. When feasible, it is preferable to delay
important treatment decisions until reversible
causes of impaired capacity are addressed (51).
Search diligently for potential
surrogates. For many individuals who are
initially thought to be unrepresented,
a diligent search often finds an available
surrogate. Therefore, before enacting
institutional or judicial mechanisms for the
unrepresented, many state laws and medical
society policy statements first require careful
documentation of diligent efforts to locate
family or close friend surrogates (52, 53).
Processes include examining personal effects,
health records, and other social services
records (51). Other processes include
searching social media, contacting neighbors,
and even hiring a private investigator (33).
Family or close friends are preferred
over institutional or judicial decision-
making. First, they are more likely to know
the patient’s values and preferences (54).
Second, involving family or a trusted friend
in medical decisions is a highly valued
aspect of community in most societies.
Third, most patients want a trusted family
member or friend to be involved in their
treatment decisions (7). Fourth, most states
include these individuals on a statutory
hierarchical order of surrogate decision-
making. For these reasons, the search for
potential surrogates should be aggressive
and rigorous (51). Even if a surrogate is not
identified, this search process may reveal
information about the patient’s values and
preferences that can guide treatment
decisions (and is itself a manifestation of
respect for persons).
Involve individuals who know and care
for the patient. Clinicians can learn
important information about a patient’s
preferences and values from people who are
not willing or permitted to function as
a surrogate. These individuals may know
and care about the patient and can play
a valuable role as “adviser” even if not as
“decider.” Consulting with these individuals
is a way to ensure that all pertinent
information about the patient is considered.
Unfortunately, many state laws are
narrow and do not formally recognize some
potential surrogates who may know and
care about the patient (17). Some states
recognize only a few types of family
members. Some states do not recognize
domestic partners or “close friends” to
make decisions when no family member is
available (55). Nevertheless, nearly 10% of
patients select nonrelatives as their
healthcare agents (56). Clinicians are often
unfamiliar with these laws, which vary
considerably from state to state (3, 57–59).
Table 4. Policy Recommendations for Medical Decision-Making for Unrepresented
Patients in Intensive Care Medicine
Recommendation 1 Institutions should promote advance care planning to prevent
patients at high risk for becoming unrepresented from
meeting this definition, both 1) by helping adult patients with
decision-making capacity to identify a preferred surrogate
decision-maker and to record their preferences and values
in an advance directive and 2) by ensuring that such
documents are widely available to clinicians at the point of
care.
Recommendation 2 Institutions should implement strategies to determine whether
seemingly unrepresented patients are, in fact,
unrepresented, including 1) carefully assessing capacity, 2)
diligently searching for potential surrogates among the
patient’s family and friends, and 3) involving any nonhospital
individuals who have shown care and concern for the
patient’s welfare and are familiar with the patient’s
preferences and values.
Recommendation 3 Institutions should manage decision-making for unrepresented
patients using collaboration between the clinical team and
a diverse interprofessional, multidisciplinary committee rather
than ad hoc by treating clinicians.
Recommendation 4 Institutions should use all available information on the
patient’s preferences and values to guide treatment
decisions. If such information is not available, the
committee should collaborate with the treatment team to
make decisions in the patient’s best interest.
Recommendation 5 Institutions should manage decision-making for
unrepresented patients using a fair process that comports
with procedural due process, such as transparency,
legitimacy, and consistency.
Recommendation 6 Institutions should employ this fair process even when state
law authorizes procedures with less oversight.
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In fact, clinicians may seek the involvement
of such nonhospital individuals, even when
state law is too narrowly constructed to
officially authorize them as surrogates (7).
Although this is not specifically authorized,
it is not prohibited. Furthermore, clinicians
may seek relevant information from
individuals who are uncomfortable with
formally assuming the role of surrogate
decision-maker.
Recommendation 3
Institutions should manage decision-
making for unrepresented patients using
collaboration between the clinical team
and a diverse interprofessional,
multidisciplinary committee rather than
ad hoc by treating clinicians.
Risks of ad hoc decisions by treating
clinicians. Commonly, treating clinicians
assume sole decisional authority when
caring for unrepresented ICU patients (6,
12). However, this is problematic for four
key reasons. First, there is well-documented
variability between clinicians in their
judgments about what is appropriate care
in such cases, raising the concern of undue
variability in treatment decisions (60–65).
Second, the perspectives of ICU clinicians
about preferences for end-of-life care often
differ significantly from the perspectives of
patients and their family members (66–70).
Third, removing the need for clinicians to
justify or explain a treatment plan may
eliminate an incentive to carefully consider
the plan of care (12). Fourth, giving
clinicians unilateral authority risks
introducing bias and conflicts of interest.
Indeed, most state laws prohibit hospital
employees from serving as patient-
designated healthcare agents or court-
appointed guardians for this very reason
(71).
Advantages of an interprofessional,
multidisciplinary process. Although
entrusting decision-making to a single
individual may be efficient, this advantage
must be weighed against the plurality of
views represented in a larger committee. In
nonemergencies, institutional mechanisms
are preferred to ad hoc strategies by
clinicians because they can safeguard key
elements of procedural fairness, including
transparency, legitimacy, consistency, and
the opportunity for appeal and review
(72–74).
An interprofessional, multidisciplinary
process will improve framing of decisions,
putting specific clinical decisions at hand
into the broader context of what is known of
the patient’s values and goals and the likely
prognosis relative to the burdens of
interventions (e.g., what probability of
recovery, to what level of health, in what
time period, and with that burdens?). There
are communication techniques that are
employed with surrogates (e.g., best case,
worst case, or most likely case) that can be
extrapolated to diverse interprofessional,
multidisciplinary committees to ensure that
all relevant factors have been considered to
explain to other people the clinical
situation, the decisions at hand, and the
reasoning behind the plan of care (75).
Procedural fairness is especially
important, because the cases in question are
often ethically controversial, have important
interests at stake, and do not have explicit
rules that can be mechanically applied (76,
77). Moreover, these cases inherently
involve patients who are vulnerable by
virtue of critical illness and incapacity and
who have little choice regarding their
treating clinicians. It is ethically important
to incorporate multiple perspectives to
minimize the risk that the values of any one
individual carry undue weight. Within
institutions, a process-based approach may
lessen arbitrariness by ensuring broader
input, consistency, transparency, and the
possibility for continuous institutional
learning about how to manage future cases
(72, 78, 79).
There are several potential criticisms
of institutional interprofessional,
multidisciplinary management. Compared
with ad hoc management by clinicians,
institutional management strategies 1)
potentially have a higher administrative
burden; 2) might constrain clinician
autonomy; 3) may require more time;
and 4) could lead to groupthink, such
that pressure to agree results in failure to
think critically and premature closure
(20, 80).
However, these possible disadvantages
are mitigated because interprofessional,
multidisciplinary management strategies
can use existing resources (e.g., the
institutional ethics committee) and can be
tailored to the capabilities of the individual
institution (81, 82). There are techniques to
elicit all options and arguments, such as
assigning one member to make the case for
limiting life-sustaining interventions and
another to make the case for continuing
them. Furthermore, the possible
disadvantages are outweighed by the
importance of maintaining procedural
fairness and the need to protect particularly
vulnerable patients.
Composition of the interprofessional,
multidisciplinary committee. To ensure
logistical feasibility, institutions should have
flexibility in how to form the diverse
interprofessional, multidisciplinary
committee. For example, it may be desirable
to form a subcommittee from a larger
standing committee that already
has the requisite interprofessional,
multidisciplinary representation, such as an
ethics committee. Similarly, institutional
policies might assign certain processes to
one or more members to accommodate local
resources and to enhance efficiency. For
example, the individual responding to
a request for ethics consultation may also
initiate convening the interprofessional,
multidisciplinary committee and may
delegate tasks to committee members.
Whenever possible, the
interprofessional, multidisciplinary
committee should include three to five
members, including a physician, a nurse,
and one person who is neither (e.g., a
chaplain or social worker). Whenever
possible, this committee should include
representation from social work, the ethics
committee, and the community (83, 84).
The committee should not include
members of the primary treatment team or
its medical consultants (23). Ideally, the
committee is diverse in terms of role,
gender, and socioeconomic status.
Recommendation 4
Institutions should use all available
information on the patient’s preferences
and values to guide treatment decisions.
If such information is not available, the
committee should collaborate with the
treatment team to make decisions in
the patient’s best interest.
The diverse interprofessional,
multidisciplinary committee and treating
clinicians should use all available
information on the patient’s preferences
and values to make the medical decision
that is maximally consistent with them
under the circumstances. Upon admission,
most unrepresented patients do not have
a clearly applicable advance directive or
Provider Orders for Life-Sustaining
Treatment (POLST). Regardless, the
interprofessional, multidisciplinary committee
should attempt to infer patients’ goals, values,
or wishes from evidence of the patient’s
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religious, spiritual, personal, cultural,
philosophical, and moral beliefs and ethics.
Even though the patient is unrepresented,
the interprofessional, multidisciplinary
committee may still have some evidence of an
unrepresented patient’s preferences from an
advance directive, medical record notes,
previous healthcare decisions, or
conversations with healthcare workers
who previously cared for the patient.
When there is no reliable evidence of
the patient’s expressed wishes, values, or
preferences, the committee should apply
the best interest standard. Typically, these
seven factors guide application of the best
interest standard: 1) the patient’s present
level of physical, sensory, emotional, and
cognitive functioning; 2) quality of life, life
expectancy, and prognosis for recovery with
and without treatment; 3) the various
treatment options and the risks, side effects,
and benefits of each; 4) the nature and
degree of physical pain or suffering
resulting from the medical condition; 5)
whether the medical treatment being
provided is causing or may cause pain,
suffering, or serious complications; 6) the
pain or suffering to the patient if the
medical treatment is withdrawn or
withheld; and 7) whether any particular
treatment would be proportionate or
disproportionate in terms of the benefits to
be gained by the patient versus the burdens
caused to the patient (33).
Recommendation 5
Institutions should manage decision-
making for unrepresented patients using
a fair process that comports with
procedural due process such as
transparency, legitimacy, and consistency.
Described below are eight proposed
components of due process for a model
institutional policy (Table 5). These are
broadly informed by the substitute
decision-making literature, philosophical
conceptions of fairness and procedural
justice, and prior professional society
guidelines.
1. Early identification of incapacitated
and potentially unrepresented patients.
Comprehensive efforts should be
made by the admitting staff and treatment
team early after admission to identify
a surrogate for patients lacking decision-
making capacity. When it appears that
the patient will be unrepresented
because a surrogate cannot be found,
the interprofessional, multidisciplinary
committee should be consulted. This will
ensure timely decision-making. If the
care team or institution subsequently finds
an appropriate surrogate, then that
individual assumes decision-making
authority.
2. The interprofessional, multidisciplinary
committee convenes to confirm that a diligent
search was completed and that the patient is
unrepresented. Before making treatment
decisions on the patient’s behalf, the
interprofessional, multidisciplinary
committee should first confirm that the
patient is, in fact, unrepresented. First,
the committee should carefully
document both prior efforts to
determine the patient’s capacity and
confirm that the patient lacks capacity.
Second, the committee should review
prior efforts to locate potential
surrogates and confirm that there is no
available surrogate. After confirming
that the patient is unrepresented,
the committee should inform the patient
(if possible) of how the committee
will proceed in the decision-making
process.
3. The interprofessional, multidisciplinary
committee diligently gathers information
about the patient’s condition, goals of care,
and values. The interprofessional,
multidisciplinary committee should meet
with the attending clinician and team and
ascertain the patient’s condition, medical
history, social history, and prognosis. The
committee should obtain a second opinion
from another independent clinician with
expertise in the patient’s condition,
addressing both the patient’s prognosis
and the recommended treatment plan.
Consistent with Recommendations 3 and 4
above, the committee should also gather
and review evidence (if any) on the
patient’s values and preferences, including
religious and moral beliefs, and record
these in the medical record. Generally, the
committee should follow the instructions in
an advance directive, POLST, or similar
document, if available. However, such
information is almost never dispositive
of what care should be administered (85).
The specific medical circumstances
confronting a patient in the ICU and the
decisions that need to be made in these
circumstances are extremely difficult to
anticipate.
4. The interprofessional, multidisciplinary
committee engages with the clinical team to
deliberate and make treatment
decisions. The interprofessional,
multidisciplinary committee should engage
with the clinical team to deliberate andmake
treatment decisions. The institutional policy
should establish whether the committee is
serving as a surrogate in a shared decision-
making model with the treatment team
(making the treatment decision) or acting in
an advisory and oversight role (providing
recommendations and ensuring soundness
of deliberations). Either way, the committee
should explain the basis for its decisions or
recommendations, especially how they are
consistent with the patient’s values and
priorities, if they are known. If such
information is not available, the committee
should explain how the decision promotes
the patient’s best interest by maximizing
benefit and minimizing burden.
The committee should not approve any
treatment decision on the basis of the
patient’s age, race, color, religion, ancestry,
national origin, disability, gender, gender
identity, gender expression, sexual
orientation, or ability to pay, unless such
a factor is clearly clinically relevant or is
pertinent to the patient’s known values,
Table 5. Summary of Components of Institutional Policy
Component 1 Early identification of incapacitated and potentially unrepresented
patients
Component 2 Interprofessional, multidisciplinary committee confirms that
a diligent search was completed and that the patient is
unrepresented
Component 3 Interprofessional, multidisciplinary committee diligently gathers
information about patient’s condition, goals of care, and values
Component 4 Interprofessional, multidisciplinary committee engages with clinical
team to deliberate and make treatment decisions
Component 5 Expedited processes for time-pressured nonemergency decisions
Component 6 Periodic retrospective review of cases
Component 7 If applicable, follow recommended processes for potentially
inappropriate treatment
Component 8 Guardianship for ongoing cases
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such as a Jehovah’s Witnesses patient’s wish
not to receive blood products. The committee
should always advocate for the provision of
appropriate pain relief and palliative care.
5. Expedited processes for time-pressured
nonemergency decisions. When time
pressures (such as a rapidly deteriorating
clinical condition) make it infeasible to
convene a diverse interprofessional,
multidisciplinary committee, clinicians
should endeavor to achieve as much
procedural oversight as the clinical
situation allows. Whenever possible, clinicians
should obtain confirmation from a clinical
ethics consultant or from an independent
clinician that an expedited process is necessary.
In situations in which decisions must be made
so quickly that no procedural oversight is
possible, there should be retrospective review.
Clinicians should, to the extent possible, not
allow situations to become time pressured. It is
ethically “troublesome” to wait “until the
patient’s medical condition worsens into an
emergency so consent to treat is implied” (8).
6. Periodic retrospective review of cases. A
mechanism for periodic retrospective review
of decisions for unrepresented patients
should be a component of an institutional
policy. A regular review process, such as a
closed session of an unrepresented morbidity
and mortality conference, helps to achieve
efficient and consistent management of cases
and may identify areas for improvement in
institutional practices (86).
7. If applicable, follow recommended
processes for potentially inappropriate
treatment. If the care team believes that the
interprofessional, multidisciplinary
committee is requesting interventions that
are futile or potentially inappropriate, they
should refer to the 2015 multiorganization
consensus statement on responding to
requests for futile or potentially
inappropriate interventions in the ICU
(86). In these cases, a formal ethics
consultation and review by the hospital’s
ethics committee should be initiated.
Both to ensure due diligence and to
avoid role confusion, the interprofessional,
multidisciplinary committee in this
process should not be the same
committee promoting procedural fairness
on behalf of the unrepresented patient.
In cases of persistent disagreement, if
feasible on the basis of local laws and
resources, the institution should consider
initiating the appropriate processes in its
jurisdiction to obtain a legal guardian or
conservator.
8. Guardianship for ongoing cases. A
goal of this document is to identify a process
by which clinicians can provide
nonemergent medical care for an
unrepresented patient without a surrogate’s
consent. The number and complexity of
decisions for unrepresented patients may
increase as these patients become sicker.
However, sometimes the care team expects
an unrepresented patient to remain
incapacitated with ongoing healthcare
needs for a considerable length of time.
In these cases, if feasible on the basis
of local laws and resources, the
institution should consider initiating the
appropriate processes in its jurisdiction to
obtain a legal guardian or conservator (11).
Recommendation 6
Institutions should employ this fair
process even when state law authorizes
procedures with less oversight.
Some state laws authorize clinicians
to make treatment decisions on behalf
of unrepresented patients with little
or no oversight (Table 2) (87–91).
Yet, because of the vulnerability of
unrepresented patients, hospitals
within these jurisdictions should
still use a diverse interprofessional,
multidisciplinary committee. In these
states, attending clinicians may be
the officially recognized decision-makers,
but they should still consult with an
interprofessional, multidisciplinary
committee and follow the above due
process and institutional policy. To
reconcile this policy statement with the
law in these states, the committee may
function in an advisory and consultative
capacity rather than in a decision-making
capacity.
Conclusions
Unrepresented patients in the ICU are
particularly vulnerable. Consequently,
treatment decisions on their behalf
should be evaluated carefully. This
policy statement is designed to help
clinicians and hospital administrators
design fair and practical procedures
for making treatment decisions on
behalf of unrepresented patients in the
ICU setting. n
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